Section 4 of 6
Clinical evidence
119 evidence topics · 16 sources
Study summaries
LOGGIC/FIREFLY-2
Objective
First-line pLGG: comparison of tovorafenib with standard-of-care chemotherapy
“The primary objective is to compare the ORR of tovorafenib monotherapy (Arm 1) vs. investigator’s choice of SoC chemotherapy (Arm 2) as assessed by the IRC per RANO-LGG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“criteria in pediatric and young adult patients with LGG harboring an activating RAF alteration who require first-line systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory role: confirmatory trial for the relapsed or refractory accelerated approval
Location and study date
Study start, sites, and countries
Collaboration with the SIOPe Brain Tumour Group LOGGIC consortium
Timelines for primary analysis and regulatory reports
Study design
Randomized, open-label, two-arm design with stratification and crossover
“LOGGIC/FIREFLY-2 ( NCT05566795 ) is a two-arm, randomized, open-label, multicenter, global, phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy vs. SoC chemotherapy in patients with pLGG harboring an activating RAF alteration who require first-line systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization between treatment arms will be stratified by primary location of the tumor (supratentorial midline vs. other), type of genomic RAF alteration (fusion vs. mutation), CDKN2A status (deletion vs. wild-type/unknown), and infant chiasmatic-hypothalamic glioma (CHG) diagnosis (yes vs. no). Patients who experience progressive disease in Arm 2 can crossover to Arm 1 and receive tovorafenib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total length of the study, from screening through to the end of the study is expected to be seven years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol amendment: RAPNO-LGG replaced RANO-LGG as the primary response criteria
Independent data monitoring committee
“To ensure a high level of safety monitoring during this trial, an independent Data Monitoring Committee (DMC) has been established and will meet periodically to review safety and efficacy data across the entire tovorafenib program.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Registry inclusion and exclusion criteria
Indications for first-line systemic therapy and excluded molecular alterations
“Patients must be evaluable by RANO-LGG, that is, they must have at least one measurable lesion imaged up to 28 days prior to treatment initiation that can be defined by T2/FLAIR and reproducibly measured by MRI in at least two-dimensions of at least 10 mm in size, and visible on two or more axial slices that are preferably ≤ 5 mm apart with 0 mm skip.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients < 16 years of age and patients ≥ 16 years of age, will be required to exhibit Lansky and Karnofsky performance status scores, respectively, of ≥ 70%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NF1 -driven tumors are excluded. Furthermore, patients with a tumor exhibiting activating molecular alterations in addition to activating RAF alterations are also ineligible for participation even if the tumors are histologically of a low-grade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of patients previously treated with dabrafenib plus trametinib
Treatment
Arm 1: tovorafenib once weekly
“Patients randomized to Arm 1 receive tovorafenib at a dose of 420 mg/m 2 (not to exceed 600 mg), in the form of a tablet or liquid suspension, QW, continuously on days 1, 8, 15, and 22 of 28-day (four week) cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients may continue on tovorafenib even following radiographic progression at the investigator’s discretion if there is evidence that the patient is still deriving clinical benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Arm 2: investigator’s choice of standard-of-care chemotherapy
“The Arm 2 VBL regimen comprises VBL (BSA ≥ 0.6 m 2 : 6 mg/m 2 /day, without exceeding 10 mg; BSA < 0.6 m 2 : BSA dose × 1/30 × body weight [kg]/day) administered IV QW in four-week cycles until completion of treatment at 70 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using RAPNO-LGG objective response rate as the primary endpoint
Primary endpoint in the current registry record
Functional, visual, and patient-reported secondary endpoints
Exploratory growth, neuropathy, and neuro-endocrine endpoints
“Comparison of changes in growth and development of patients between study arms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison of chemotherapy-induced peripheral neuropathy outcomes between study arms by pediatric-modified total neuropathy score in patients ≥ five years of age” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison of neuro-endocrine morbidity between study arms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Original choice of RANO-LGG to align with the dabrafenib plus trametinib registrational trial
“As this is a registrational trial, the primary efficacy endpoint in this study is based on RANO-LGG criteria, the same criteria used in registrational study CDRB436G2201 ( NCT02684058 ) of dabrafenib in combination with trametinib in pediatric patients with pLGG harboring a BRAF V600 mutation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of pLGG being a chronic disease, in addition to radiologic responses, functional endpoints such as neurologic outcomes, visual function in OPG, and patient-reported outcomes are of extreme importance and will be assessed throughout this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory view of RAPNO-LGG as the criteria developed for pLGG
“In alignment with current scientific consensus on the measurement of pLGG, FDA considered the RAPNO-LGG criteria, which assess response based on T2-weighted and T2-weighted fluid-attenuated inversion recovery imaging (T2/FLAIR signaling), most appropriate to evaluate efficacy in pLGG, which are variably non-contrast enhancing and frequently contain tumor cysts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA acceptance of ORR and a PFS key secondary endpoint for verification of benefit
“Efficacy will be assessed using a primary endpoint of ORR and key secondary endpoints of PFS and DoR as per LGG-specific criteria. Additionally, clinical outcome assessment data including evaluation of neurological function, visual function and health-related quality of life will be captured, which are particularly relevant for patients with pLGG given known tumor-related complications and the potentially indolent nature of the tumor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical relevance of minor responses included in the response rate
Limits of radiographic progression criteria and time to next treatment as a complementary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Power assumptions and hierarchical testing (design publication, RANO-LGG)
“To assess the ORR per the primary endpoint, the planned sample size of approximately 400 patients will provide around 85% power to detect a 15% improvement for the tovorafenib arm at a two-tailed level of significance of 0.05, assuming a 30% ORR in the control arm and a dropout rate of up to 10%. To assess PFS as per the key secondary endpoint, the planned sample size of approximately 400 patients will provide around 85% power to detect a hazard ratio of 0.67 for PFS at a two-tailed level of significance of 0.05, assuming the median PFS for the tovorafenib arm is 4.5 years versus a median of three years for the control arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If this test meets the pre-specified boundary for statistical significance, then the key secondary endpoints will be tested. It should be noted that the statistical analysis plan for the LOGGIC/FIREFLY-2 trial may be subject to change based on emerging data from FIREFLY-1 trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consistency of treatment effect before and after the endpoint amendment
Planned and enrolled participants
Participants analyzed
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
Participant disposition by arm
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Comparative ORR, PFS, and visual outcomes
No evidence found.
Health-related quality of life and patient-reported outcomes
Planned patient-reported outcome assessments
“PedsQL-Core, PedsQL-Cancer and PROMIS ® are being assessed at Screening, every 52 weeks from week 5 to end of treatment, and at year 5 as part of the LTFU. Arm 2 has an additional assessment at year 2 in the LTFU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcome results
No evidence found.
Safety results
Planned growth and development monitoring
Comparative safety results
No evidence found.
Study limitations
Summary: design limitations and evidence gaps for the first-line indication
LOGGIC/FIREFLY-2 is the only randomized trial of tovorafenib and the only trial in the first-line setting. As of September 2026, no efficacy, safety, or patient-reported outcome results have been reported; enrollment of approximately 400 participants (418 in the registry record) was completed in May 2026, and topline data are expected by mid-2027, with the interim report projected for April 2028 and the final report for April 2032.
The trial is open label, so investigator-assessed outcomes and patient-reported outcomes are susceptible to assessment bias; the primary endpoint relies on independent review. The primary response criteria were changed from RANO-LGG to RAPNO-LGG after 113 of 400 participants were recruited, and the EMA noted interest in the consistency of the treatment effect before and after this change. The design paper stated that the statistical analysis plan may change based on FIREFLY-1 data.
The comparator is investigator's choice among four chemotherapy regimens (two vincristine/carboplatin schedules, vinblastine, or monthly carboplatin), and participants with progression on chemotherapy may cross over to tovorafenib, which may affect interpretation of overall survival and time-to-event endpoints. ORR is a surrogate endpoint; PFS is the key secondary endpoint. The comparator does not include dabrafenib plus trametinib for BRAF V600E-mutated tumors, and participants with NF1, additional activating alterations, or prior nonsurgical therapy are excluded, which limits generalizability to these groups.
FIREFLY-1
Objective
Relapsed or refractory pLGG and advanced solid tumors
“The phase 2 FIREFLY-1 (PNOC026; NCT04775485 ) trial objective was to evaluate the safety and efficacy of tovorafenib monotherapy in children, adolescents and young adults with RAF -altered, relapsed/refractory pLGG or advanced solid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Updated analysis objectives: long-term outcomes, treatment-free interval, and retreatment
Location and study date
Sites, countries, and enrollment period
Data cutoffs of the primary, regulatory, and 3-year analyses
| Analysis | Quoted data cutoff |
|---|---|
| Primary publication and FDA review | “as of a 5 June 2023 datacut”View highlighted excerpt for this quote |
Study design
Single-arm, open-label phase 2 trial with three arms
Blinded independent central review by three response criteria
“As per the trial design, patients were initially enrolled based on investigator assessment of eligibility per RANO-HGG criteria. Investigator response assessments per RANO-HGG were also the criteria on which cessation of treatment due to PD were based. Response was subsequently analyzed per all three criteria by blinded independent central review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned treatment duration, post-treatment observation, and retreatment
Eligibility criteria
Arm 1 inclusion criteria
“In brief, eligible patients in arm 1 were aged 6 months to 25 years, inclusive, with a histopathologically verified pLGG, which had previously been treated with at least one line of prior systemic therapy with evidence of radiographic progression, a documented known activating BRAF alteration and measurable disease as defined by RANO-HGG criteria, a Lansky (aged <16 years) or Karnofsky (aged ≥16 years) performance score of ≥50 and adequate organ function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Tovorafenib dose and schedule
Study outcomes
Rationale for using RANO-HGG objective response rate as the primary endpoint
Primary and secondary endpoints
“The primary endpoint in arm 1 was ORR, defined as the proportion of patients with a confirmed response of CR or PR according to RANO-HGG criteria, as assessed by an IRC. Secondary endpoints for arm 1 included CBR, PFS, DOR and TTR, as assessed by the IRC using RANO-HGG criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ORR, CBR, PFS, DOR and TTR were also assessed by the IRC according to RAPNO criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post hoc exploratory endpoints for arm 1 included ORR and CBR according to RANO-LGG criteria by IRC assessment. For RAPNO and RANO-LGG ORR assessments, patients with confirmed MRs were considered responders in accordance with published guidelines. Changes in quality of life and health utilities measures were exploratory objectives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time to next treatment and treatment-free interval
Sponsor rationale for RANO-HGG at trial initiation
“The primary endpoint of overall response rate (ORR) was assessed per independent radiology review committee (IRC) according to Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as these were considered the only validated assessment criteria at the time of trial initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to RANO-HGG criteria, the FIREFLY-1 trial met its primary endpoint by rejecting the null hypothesis ORR of 21% observed for single-agent vinblastine in this setting” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RAPNO criteria focus on T2-weighted fluid-attenuated inversion recovery (FLAIR) imaging for assessing response in pLGG rather than changes in contrast-enhancing disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA: T2/FLAIR-based criteria preferred and RAPNO-LGG used for the regulatory analysis
“Unlike the RANO-HGG and RANO-LGG criteria, RAPNO criteria do not consider change in contrast enhancement in the measurement of response due to spontaneous changes in contrast uptake in pLGG in the absence of clinical progression, and also incorporate parameters to define a response for cysts” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EMA: RANO-HGG considered unsuitable for pLGG
Minor responses and clinical improvement in case narratives
“In the FIREFLY-1 efficacy population, 22 patients demonstrated an MR by either RANO-LGG or RAPNO criteria. Reported clinical changes included improvement in headaches, neurocognitive function, mobility, motor and verbal developmental delays, and fatigue; improvement of tumor-related medical complications including endocrinopathies; ability to attend or perform in school; and ability to engage in other age-appropriate activities of daily living.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This information was not collected in a sufficiently standardized or comprehensive manner to support an assessment of direct clinical benefit of tovorafenib; however, it provided preliminary substantiation of the clinical meaningfulness of MRs in pLGG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiographic response and visual acuity in optic pathway glioma
Radiographic progression-free survival compared with clinical progression and time to next treatment
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and statistical methods
“A sample size of 60 patients in the evaluable population was considered to provide 88% power to reject the null hypothesis ORR of 21%, at the two-sided 0.05 level, assuming that the true underlying ORR of tovorafenib was 40% in this disease population. An exact binomial test was used for hypothesis testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR and CBR were calculated with 95% CIs determined using the Clopper–Pearson method. PFS and DOR were estimated by the Kaplan–Meier method and were summarized along with the corresponding two-sided 95% CI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time-to-event endpoints considered descriptive in a single-arm trial
Enrolled and evaluable participants in arms 1 and 2
“The IRC deemed 69 patients in arm 1 who received ≥1 dose of tovorafenib to have measurable disease at baseline per RANO-HGG criteria. Seventy-six patients in arm 1 were deemed evaluable for efficacy by the IRC per RAPNO and RANO-LGG criteria, which use T2-weighted imaging for response assessment. Safety was analyzed in all patients in arms 1 and 2 who received ≥1 dose of tovorafenib ( n = 137).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Efficacy and safety analysis sets
“The primary endpoint analysis was performed in the arm 1 evaluable population, which included all enrolled patients who received at least one dose of tovorafenib and had measurable disease at baseline per RANO-HGG criteria as determined by the IRC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For this report, safety was assessed in the arm 1 and 2 safety analysis set, which comprised all enrolled patients who received at least one dose of trial treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EMA assessment of the exclusion of participants without measurable disease
Results
Participant disposition
Primary analysis (5 June 2023)
“Patients in arm 1 had received a median of 18 treatment cycles (range, 1–26), with median treatment compliance of 100% (range, 93–100)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of treatment (DOT) was 15.8 months (range, 0.7–23.7), with 66% ( n = 51) continuing treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory data cutoff (10 May 2024)
Three-year analysis (6 June 2025)
Baseline characteristics
Selected baseline characteristics by arm
| Characteristic | Arm 1 (n = 77) | Arm 2 (n = 60) | Total (n = 137) |
|---|---|---|---|
| Age, years, median (range) | “8 (2-21)” | “9.5 (1-24)” | “9 (1-24)” |
| Optic pathway primary location, n (%) | “39 (51)” | “29 (48)” | “68 (50)” |
| KIAA1549::BRAF fusion, n (%) | “56 (73)” | “45 (75)” | “101 (74)” |
| BRAF V600E mutation, n (%) | “13 (17)” | “9 (15)” | “22 (16)” |
| Three or more prior lines, n (%) | “39 (51)” | “33 (55)” | “72 (53)” |
| Prior MEK and/or BRAF inhibitor, n (%) | “46 (60)” | “37 (62)” | “83 (61)” |
| Prior radiotherapy, n (%) | “2 (3)” | “3 (5)” | “5 (4)” |
No participants younger than 2 years in arm 1
Efficacy results
Relapsed or refractory pLGG: ORR by three response criteria at the primary analysis (5 June 2023)
| Response | RANO-HGG (N = 69) | RAPNO-LGG (N = 76) | RANO-LGG (N = 76) |
|---|---|---|---|
| Complete response, n (%) | “12 (17.4)” | “0” | “0” |
| Partial response, n (%) | “34 (49.3)” | “28 (36.8)” | “20 (26.3)” |
| Minor response, n (%) | “-” | “11 (14.5)” | “20 (26.3)” |
| Stable disease, n (%) | “18 (26.1)” | “23 (30.3)” | “23 (30.3)” |
| Progressive disease, n (%) | “4 (5.8)” | “13 (17.1)” | “11 (14.5)” |
| Patients with confirmed response | “46” | “39” | “40” |
| ORR, % (95% CI) | “66.667 (54.288, 77.563)” | “51.316 (39.569, 62.957)” | “52.632 (40.844, 64.208)” |
Relapsed or refractory pLGG: duration of response, PFS, and time to response by criteria (5 June 2023)
Relapsed or refractory pLGG: clinical benefit rate and subgroups (5 June 2023)
“The ORR per RANO-HGG criteria (primary endpoint) in patients with response-evaluable disease was 67% (95% confidence interval (CI): 54–78), including 12 (17%) patients with a complete response (CR) and 34 (49%) patients with a partial response (PR). Eighteen (26%) patients had a best overall response (BOR) of stable disease (SD), giving a CBR of 93%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was similar in patients with tumors harboring BRAF fusions (52%; 95% CI: 39–64) and BRAF V600E mutations (50%; 95% CI: 21–79) and in patients who had received prior MAPKi therapy (49%; 95% CI: 34–64) and those who had not (55%; 95% CI: 36–73)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For RANO-HGG criteria, 33% (n = 15) of patients who had progressed on a MAPKi as their most recent prior therapy had a CR or a PR to tovorafenib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relapsed or refractory pLGG: regulatory data cutoff (10 May 2024)
Relapsed or refractory pLGG: 3-year update per RAPNO-LGG (6 June 2025)
| Parameter (RAPNO-evaluable, arm 1, n = 76) | Quoted value |
|---|---|
| ORR, n (%) | “40 (53)” |
| CBR, stable disease of any length, n (%) | “62 (82)” |
| CBR, stable disease ≥12 months, n (%) | “44 (58)” |
| Partial response, n (%) | “30 (39)” |
| Minor response, n (%) | “10 (13)” |
| Progressive disease, n (%) | “13 (17)” |
| Median DOR, months (95% CI) | “19.4 (13.8-27.2)” |
| Median TTR, months (range) | “5.4 (1.6-17.5)” |
| Median PFS, months (95% CI) | “16.6 (8.3-19.1)” |
| PFS rate at 24 months, % (95% CI) | “32 (21-42)” |
| PFS rate at 36 months, % (95% CI) | “20 (12-30)” |
| Median TTNT, months (95% CI) | “42.6 (36.6-NE)” |
Relapsed or refractory pLGG: treatment beyond progression
Relapsed or refractory pLGG: treatment-free interval and rebound after stopping treatment
Relapsed or refractory pLGG: retreatment after the observation period
Relapsed or refractory pLGG: prior-therapy subgroups at 3 years
Relapsed or refractory optic pathway glioma: radiographic and visual acuity outcomes
“Forty-two of 77 patients had OPGs; 35 of 42 had ≥2 VA assessments. The overall response rate in the OPG subgroup according to RANO-HGG, RAPNO, and RANO-LGG criteria were 64%, 50%, and 55%, with clinical benefit rates of 95%, 88%, and 90%, respectively. VA per patient was preserved for 80% of patients; 31% demonstrated improved VA; VA per eye was preserved in 87%, with 27% improving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
PedsQL 3.0 Cancer Module during the first year of treatment
“For the PedsQL 3.0 Cancer Module, 51 completed self-reports at BL, and 32 at C13 due to continued attrition over time. Median Total Score was 81.5 (range: 46.3-100) at BL and 85.2 (range: 50-100) at C13. At C4, 16% worsened (decrease >10 points) and 11% improved (increase >10 points); by C13, 11% worsened and 33% improved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CONCLUSIONS HRQOL generally remained stable, or improved, in the majority of patients with r/r pLGG during the first year of treatment with tovorafenib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality-of-life data not included in the EU application
Safety results
Treatment-emergent and treatment-related adverse events at 3 years (arms 1 and 2, n = 137)
| Preferred term | TEAE, any grade, n (%) | TEAE, grade ≥3, n (%) | TRAE, any grade, n (%) | TRAE, grade ≥3, n (%) |
|---|---|---|---|---|
| Any adverse event | “137 (100)” | “113 (82)” | “136 (99)” | “91 (66)” |
| Hair color changes | “106 (77)” | “0” | “106 (77)” | “0” |
| Elevated CPK | “85 (62)” | “16 (12)” | “82 (60)” | “15 (11)” |
| Fatigue | “84 (61)” | “6 (4)” | “68 (50)” | “6 (4)” |
| Anemia | “83 (61)” | “20 (15)” | “69 (50)” | “19 (14)” |
| Maculopapular rash | “69 (50)” | “11 (8)” | “63 (46)” | “11 (8)” |
| Decreased growth velocity | “61 (45)” | “46 (34)” | “60 (44)” | “46 (34)” |
| Increased ALT | “33 (24)” | “8 (6)” | “24 (18)” | “7 (5)” |
| Epistaxis | “44 (32)” | “1 (1)” | “28 (20)” | “0” |
Serious adverse events, deaths, discontinuations, and dose modifications at 3 years
Primary analysis safety (5 June 2023)
“Grade ≥3 TEAEs occurred in 63% of patients, the most common being elevated CPK (12%), anemia (11%) and maculopapular rash (8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nine (7%) patients had TRAEs leading to tovorafenib discontinuation, the most common being tumor hemorrhage (three patients) and decrease in growth velocity (two patients). TRAEs leading to dose reduction were seen in 33 (24%) patients, the most common being maculopapular rash (4%) and decreased appetite (3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No signs of ocular toxicity, adverse impact on cardiac function or abnormal weight gain were observed in children treated with tovorafenib, unlike those observed with MEK inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Growth velocity on treatment and recovery after stopping
Long-term safety uncertainty noted by the EMA
Study limitations
Summary: limitations of FIREFLY-1 as evidence for the first-line indication
FIREFLY-1 enrolled only participants with relapsed or refractory pLGG who had received a median of 3 prior lines of systemic therapy (range 1 to 10), and 61% had received a MEK and/or BRAF inhibitor; it provides no direct evidence in the treatment-naive, first-line population that is the subject of this report. It is a single-arm trial without a comparator, and the authors, the FDA, and the EMA identified this as the main limitation; PFS, OS, time to next treatment, visual acuity, and quality-of-life results are descriptive.
The protocol primary endpoint (RANO-HGG ORR, 67%) was not used by regulators: the FDA and EMA based their assessments on RAPNO-LGG ORR (51% at June 2023; 52.6% at May 2024; 53% at June 2025 in 76 evaluable participants), a protocol secondary endpoint, with minor responses included. RANO-LGG was added post hoc at regulatory request. IRC-assessed and investigator-assessed RANO-HGG ORR differed (71.0% vs 49.3% at May 2024), and treatment decisions were based on investigator RANO-HGG assessments, so 38 participants (50%) continued treatment beyond RAPNO-defined progression. Median RAPNO PFS (16.6 months) was shorter than median time to next treatment (42.6 months).
Arm 1 included no participants younger than 2 years, 51% had optic pathway tumors, 74% had KIAA1549::BRAF fusions, and participants with NF1 or additional activating alterations were excluded. Race and ethnicity diversity was limited. Only 3 participants with BRAF V600E mutations had received dabrafenib plus trametinib. Quality-of-life data are available only as a congress abstract with attrition from 51 to 32 respondents by cycle 13. The growth analysis required at least 6 months of treatment and off-treatment height data, and adult height outcomes are not yet known. Evidence on retreatment is limited to 8 participants.
Single-arm design
Post hoc visual acuity analysis
“The main limitation of this analysis of VA outcomes in patients with OPG enrolled in arm 1 of the FIREFLY-1 trial is that it is a post hoc investigation, conducted in the absence of power calculations; analyses are consequently not powered to allow the drawing of definitive conclusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PNOC014
Objective
Maximum tolerated or recommended phase 2 dose in children with recurrent MAPK-altered tumors
Location and study date
Treatment periods
Participating sites
No evidence found.
Registry record: sponsor, study status, and actual start and completion dates
| Field | Registry record |
|---|---|
| Sponsor | “Karen D. Wright, MD” |
| Responsible party | “Karen D. Wright, MD, Dana-Farber Cancer Institute” |
| Study status | “Completed” |
| Study start (actual) | “2018-02-27” |
| Primary completion (actual) | “2025-12-31” |
| Study completion (actual) | “2025-12-31” |
| Last update posted | “2026-02-19” |
Study design
Phase IA 3 + 3 escalation and phase IB subgroup-specific design
Eligibility criteria
Inclusion and exclusion criteria
Treatment
Dose levels and treatment duration
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Primary endpoint, toxicity grading, and response assessment
Statistical analysis description
Number of participants (Planned and analyzed)
Bayesian subgroup-specific dose finding
Treated and evaluable participants
Description of analysis sets
Toxicity and response-evaluable sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Relapsed or recurrent pLGG and other MAPK-altered tumors: phase IA and IB responses
FDA consideration as confirmatory evidence
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose-limiting toxicities and recommended phase 2 dose
Common adverse events and laboratory abnormalities
Growth suppression
Study limitations
Summary: limitations of PNOC014
PNOC014 was a phase 1, nonrandomized, dose-finding study in 44 participants aged 1 to 25 years with recurrent or progressive MAPK pathway-altered tumors (38 low-grade and 6 high-grade tumors) at 15 US sites; it did not include treatment-naive participants. The design was changed mid-study from a 3 + 3 escalation to a Bayesian subgroup-specific design, and doses ranged from 280 to 530 mg/m2, so response data are pooled across dose levels. Responses were reported with stable disease counted as response (25 of 27 centrally reviewed participants, 93%), central and institutional assessments were discordant in 13 of 31 participants, and pharmacokinetic sampling in phase IB was disrupted by COVID-19 travel restrictions. The FDA stated that limited data from this study precluded its acceptance as a second adequate and well-controlled trial.
Authors’ discussion of heterogeneity of response
C28001
Objective
First-in-human study in adults with advanced solid tumors
“Primary objectives were to evaluate the safety of tovorafenib administered once every other day (Q2D) or once weekly (QW), and to determine the maximum-tolerated and recommended phase 2 dose (RP2D) on these schedules. Secondary objectives included evaluation of antitumor activity and tovorafenib pharmacokinetics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Enrollment period and data cutoff
“Between September 13, 2011 and September 5, 2016, 149 patients were enrolled and received at least 1 dose of tovorafenib (safety population).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data cutoff date for the current analysis was April 11, 2017, at which time, a small number of patients remained on treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry record: sponsor, actual study dates, and number of study locations
| Field | Registry record |
|---|---|
| Sponsor | “Millennium Pharmaceuticals, Inc.” |
| Responsible party | “Takeda (Millennium Pharmaceuticals, Inc.)” |
| Study status | “Completed” |
| Study start (actual) | “2011-09-15” |
| Primary completion (actual) | “2017-04-11” |
| Study completion (actual) | “2018-10-16” |
| Study locations | “This study has 16 locations” |
| Last update posted | “2020-08-10” |
Study design
Dose escalation and melanoma dose expansion
“We conducted a first-in-human, phase 1, multicenter, open-label study of tovorafenib in patients with relapsed or refractory advanced solid tumors. The study included a dose escalation phase and a dose expansion phase, with the latter including molecularly defined cohorts of patients with locally advanced, metastatic, and/or unresectable melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was initially designed to investigate a Q2D schedule. Subsequently, a protocol amendment introduced planned QW dose escalation cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Adult participants
“Eligible patients were aged ≥ 18 years, with relapsed or refractory advanced solid tumors (excluding lymphoma but including melanoma), who had progressed on/after, or were not candidates for standard therapies or for whom no approved therapy was available” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Fasting oral administration and dose levels
“Tovorafenib was administered orally (tablet formulation), with patients fasting (except for water) for at least 2 h before and at least 2 h after taking their dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Planned QW doses to be administered on days 1, 8, 15, and 22 of a 28-day cycle were a starting dose of 400 mg, followed by dose level increases of 200 mg (i.e., doses of 600 mg, 800 mg, and 1000 mg) in each subsequent cohort until the MTD/RP2D was reached.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Safety, dose-limiting toxicity, response, and pharmacokinetic assessments
“Following baseline evaluation, response was assessed by investigators every two cycles by computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (version 1.1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
No formal power calculation
“No formal power calculations were carried out. In the dose escalation phase, enrollment of approximately 54 patients was envisaged, with the actual number dependent on the number of dose escalation steps and the number of patients per cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants by schedule
“Tovorafenib was administered Q2D to 30 patients in the dose escalation phase and 80 patients in the dose expansion phase (including 20 patients in a PK expansion cohort) and QW to 20 patients in the dose escalation phase and 19 patients in the dose expansion phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety, DLT-evaluable, response-evaluable, and PK-evaluable populations
“The safety population was defined as all patients who received any amount of tovorafenib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response-evaluable population included all patients with measurable disease who received any amount of tovorafenib and who had at least 1 postbaseline response assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Treatment exposure and discontinuation
“Patients received a median of 2 cycles of treatment in both the dose escalation and dose expansion phases. The primary reasons for treatment discontinuation were disease progression and adverse events (Supplementary Tables S2 and S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Primary diagnoses
“The most common primary diagnoses in the dose escalation phase were colon cancer and melanoma. In line with the eligibility requirements, most patients in the dose expansion phase had a primary diagnosis of melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Adult melanoma and solid tumors: responses by cohort
“Responses were seen in 10 (15%) of 68 evaluable patients in the Q2D expansion phase, including in 8 of 16 (50%) patients with BRAF mutation-positive melanoma naïve to RAF and MEK inhibitors. In the QW dose expansion phase, there were no responses in 17 evaluable patients with NRAS mutation-positive melanoma naïve to RAF and MEK inhibitors; 9 patients (53%) had a best response of stable disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics of once-weekly dosing
“The mean plasma terminal half-life ( t 1/2 ) of tovorafenib was approximately 70 h (range 31–119 h) as defined in 20 evaluable patients receiving 600 mg QW.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While no apparent accumulation was observed with the QW dose regimens, Q2D administration resulted in approximately 2.5-fold accumulation in AUC 48 at steady state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Recommended phase 2 dose and dose-limiting toxicities
“In the QW dose escalation phase, cohorts of patients received tovorafenib doses of 400 mg, 600 mg, and 800 mg, in 28-day cycles. DLTs occurred in cycle 1 in 2 patients in the 800 mg cohort; 1 patient had grade 3 hyperbilirubinemia and 1 had grade 3 rash. The MTD selected for the QW expansion cohort was therefore 600 mg to be administered over 28-day cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 or higher adverse events, discontinuations, and deaths
“In the dose expansion phase, 68% of patients experienced a grade 3 or higher TEAE, including 73% of patients in the Q2D cohorts and 47% in the QW cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the QW cohort of the dose expansion phase, 4 of 19 patients (21%) had TEAEs resulting in permanent discontinuation, including atrial flutter, dyspnea, erythema multiforme, and fatigue (1 patient each).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 13 on-study deaths. The fatal SAEs associated with these deaths predominantly related to the underlying disease or complications thereof and are listed in Supplementary Table S8. Only one death, associated with respiratory failure in a patient in the 280 mg Q2D dose escalation cohort, was deemed by the study investigators to be treatment related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limited relevance of C28001 to pLGG
C28001 enrolled 149 adults (median age 62.5 to 66.0 years across phases) with relapsed or refractory advanced solid tumors, mostly melanoma and colon cancer; it included no participants with pLGG and no children. Dosing was flat (600 mg once weekly recommended) and fasting was required, whereas pediatric trials used body surface area-based dosing without food restrictions. No formal power calculations were performed, response was investigator assessed by RECIST 1.1 without independent review, and median treatment exposure was 2 cycles, so the study provides no information on long-term toxicities relevant to children such as growth velocity. Its relevance to this report is limited to the safety profile in adults, the once-weekly schedule, and pharmacokinetics (mean terminal half-life of approximately 70 hours at 600 mg once weekly).